The FDA approved obinutuzumab (Gazyva) or use in combination with chlorambucil to treat patients with previously untreated CLL, ibrutinib (Imbruvica) received FDA approval for the treatment of mantle cell lymphoma, and other FDA actions.
In patients with resectable hypopharyngeal and laryngeal cancers, a trend toward worse HRQOL scores was found in patients receiving alternating chemoradiotherapy compared to patients receiving sequential induction chemotherapy and radiotherapy.
A definitive trial has indicated that low-level laser therapy reduces the occurrence of canker sores and improves quality of life in patients with head and neck squamous cell carcinoma who are undergoing concurrent chemoradiotherapy.
This fact sheet reviews the details of head and neck cancer, including locations, causes, symptoms, diagnosis, risk reduction, and treatment.
Persons with head and neck cancer who are undergoing radiation or chemoradiation can preserve swallow function by exercising involved muscles before, during, and after treatment.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|